RINVOQ

This brand name is authorized in Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug RINVOQ contains one active pharmaceutical ingredient (API):

1 Upadacitinib
UNII NEW4DV02U5 - UPADACITINIB HEMIHYDRATE

Upadacitinib is a selective and reversible JAK inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. It is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients.

Read about Upadacitinib

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
RINVOQ Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L04AF03 L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 11979L, 11989B
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 543720060004207, 543720060004307
Country: CA Health Products and Food Branch Identifier(s): 02495155
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 5591-MEE-1020, 7080-MEE-0322
Country: EE Ravimiamet Identifier(s): 1808951, 1808962, 1808973, 1809312, 1809323, 1860588, 1860601, 1860612, 1860623, 1887857, 1887891
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1191404001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 091893
Country: FR Base de données publique des médicaments Identifier(s): 65852428
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 380675
Country: HK Department of Health Drug Office Identifier(s): 66872
Country: IE Health Products Regulatory Authority Identifier(s): 89057, 89155
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 8740, 9072, 9307
Country: JP 医薬品医療機器総合機構 Identifier(s): 3999048G1028, 3999048G2024, 3999048G3020, 3999048G4027
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1089080, 1089081, 1089082, 1089083, 1089084, 1093301, 1093302, 1093303, 1093304
Country: NL Z-Index G-Standaard, PRK Identifier(s): 201073
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 20573, 22034
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100427770
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W66589001, W68028001, W69486001, W69486002
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8680656080575, 8680656080582
Country: US FDA, National Drug Code Identifier(s): 0074-2306
Country: ZA Health Products Regulatory Authority Identifier(s): 54/3.1/0187

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.